# Bioequivalence Study of Pediatric Formulations to Treat HIV Infection

> **NCT01469520** · PHASE1 · UNKNOWN · sponsor: **Elim Pediatric Pharmaceuticals Inc.** · enrollment: 24 (actual)

## Conditions studied

- HIV
- AIDS

## Interventions

- **DRUG:** Epivir®, Retrovir® and Viramune®
- **DRUG:** Lamivudine, Zidovudine and nevirapine
- **DRUG:** Lamivudine, zidovudine, nevirapine

## Key facts

- **NCT ID:** NCT01469520
- **Lead sponsor:** Elim Pediatric Pharmaceuticals Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-10
- **Primary completion:** 2011-11
- **Final completion:** 2011-12
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2011-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01469520

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01469520, "Bioequivalence Study of Pediatric Formulations to Treat HIV Infection". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01469520. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*